Elisha Y. Goldberg
Keine laufenden Positionen mehr
Profil
Elisha Y.
Goldberg, with a middle initial of Y., worked as a Director of Business Development at Angion Biomedica Corp.
Ehemalige bekannte Positionen von Elisha Y. Goldberg
| Unternehmen | Position | Ende |
|---|---|---|
| ANGN BIOM | Corporate Officer/Principal | 31.01.2022 |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Private Unternehmen | 1 |
|---|---|
Angion Biomedica Corp.
 Angion Biomedica Corp. Pharmaceuticals: MajorHealth Technology Angion Biomedica Corp. operates as a biopharmaceutical company. The firm focuses on the discovery and development of novel therapeutic agents to address acute organ injuries and fibrotic diseases. Its product pipeline includes ANG-3777, ANG-3070, ROCK2 Inhibitor and CYP11B2 Inhibitors. The company was founded by Itzhak D. Goldberg on April 6, 1998 and is headquartered in Newton, MA. | Health Technology |
